World Conference Calendar

33818 Conferences

Onsite GCP Review and Update including the all-important 'Investigators Responsibility' 2017

Added by globalcompliancepanel on 2017-09-06

Conference Dates:

Start Date Start Date: 2017-11-02
Last Date Last Day: 2017-11-03
Deadline for abstracts/proposals Deadline for abstracts/proposals: 2017-11-01

Conference Contact Info:

Contact Person Contact Person: Event Manager
Email Email:
Address Address: Baltimore, Baltimore, MD, United States
Phone Tel: 800-447-9407
Phone Fax: 302-288-6884

Conference Description:

Course "Onsite GCP Review and Update including the all-important 'Investigators Responsibility'" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.


This seminar is designed to acquaint all Participants with the Rules and Regulations that form the background of what is know as the GCP of Clinical Research. To follow "The Good Clinical Practices" (GCP) is to follow the standard for the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of clinical trails that provides assurance that the data and reported results are credible and accurate and, most importantly, that the safety, rights, integrity, and confidentiality of trial subjects is protected.
That all members of the team must know and practice "GCP" guarantees, that the Protocol is followed, that the Informed consent is complete, that the study conduct is according to the protocol, that Adverse Events are correctly recorded and that the Principal Investigator knows well her/his responsibilities to follow what "GCP" stands for

Why you should attend:

It is now reasonable to expect that the Sponsor's should become more discerning regarding the GCP qualifications and training of the staff of any unit conducting studies on human volunteers. Investigators, as well as all site staff, must know how to assess how well the unit is complying with the regulation and the essence of GCP to assure the safety of the volunteers as this ultimately affects the safety of the public. Following GCP is also an assurance of a clean audit.

Areas Covered in the Session:

Session 1:
What was the reason the ICH was formed
What is the essence of GCP
How does You QA group insure GCP
The PI/Investigators role in GCP
The Sponsors role in GCP
What is the end result of Dose response studies
Does your Unit/CPU/CRU follow the 13 GCP Principles?
How following the signed Protocol is GCP
Session 2:
Investigators key role in the Clin. Research process
How following GCP helps assure a clean Audit
What are the main Investigator responsibilities?
How is the investigator is responsible for the IC?
What is the legal language of the FDA form 1572?
Why is Financial Disclosure information important?
Session 3:
The Primacy of the study Protocol
The Pi responsibility in the Protocol development
The Sponsors Responsibility in Protocol development
How to be sure the protocol is safe for the subjects
How to be sure the protocol is scientifically valid
How to insure the to protocol is ethically valid
Session 4:
What is a Protocol "Deviation" and other terms
The Regulatory requirements for handling protocol deviations and violations
Importance of documentation of protocol deviations
What is the reason different IRBs define deviations and violations differently
What is the basis of the difference between a "Deviation" and a "Violation"
Session 5:
The historical background of why accurate data is essential for ensuring safety of study participants/Pt
The purpose of ensuring that all data is accurate, legible, contemporaneous, original and attributable
The regulatory requirements for care of source documents
What "To Do" and "Never Do" with regard to data including corrections?
What documents does the FDA review - always?
Session 6:
How to Assess and report AEs and SAEs
The CFR definitions of AEs, SAEs, and many more
How to know an Adverse Event and when to report it
Understanding laboratory AEs and the "Reference Range" concept
Common Mistakes in AE / SAE Reporting
Reporting of Adverse Events - when and to whom
how Data safety Monitoring in Protects Volunteers
Session 7:
The Sponsor's responsibility in quality monitoring
Why Monitor Clinical Studies
What does a Monitor look for?
How does a Sponsor or Site prepare for an Audit
What are the strategies to improve an audit outcome?
What does the FDA look at when Auditing/Inspecting a study?
What types of studies are targeted for auditing
Session 8:
The function of/reasons for an SOP in a CPU/CRU
How SOPs are set up
What areas of CPU management need SOPs
Who creates an/the SOPs
Who is responsible for the Unit's SOPs

Who will benefit:

This lecture series will provide invaluable assistance to industry study sponsors and those involved in Setting up the IND to follow the regulatory / legal responsibilities and also the ethical considerations in pharmaceutical product (IMP) research involving human subjects. Those benefiting the most would be:
The Study Sponsor
Principal Investigators and sub investigators
Clinical Research Scientists (PKs, Biostatisticians,

Read More: trol/globalseminars/~product_id=901348SE MINAR?worldconferencecalendar-November-2 017-SEO
© 2017 World Conference Calendar. All rights reserved.
About WCC | News | FAQs | Links | Terms and Conditions | Privacy | Contact Us